MDxHealth Signs on FedMed, ACPN for Increased Access to ConfirmMDx Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth today announced it signed agreements with health insurance providers FedMed and America's Choice Provider Network, extending access to the company's ConfirmMDx prostate cancer test to 50 million additional lives.

FedMed has 40 million covered lives, while ACPN has 11.2 million lives, MDxHealth said. The firm said that more than 130 million covered lives now have access to the ConfirmMDx test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.